MEI Pharma, Inc. (MEIP)
NASDAQ: MEIP · IEX Real-Time Price · USD
3.655
+0.795 (27.80%)
Jul 22, 2024, 10:24 AM EDT - Market open
MEI Pharma Employees
MEI Pharma had 46 employees as of June 30, 2023. The number of employees decreased by 56 or -54.90% compared to the previous year.
Employees
46
Change (1Y)
-56
Growth (1Y)
-54.90%
Revenue / Employee
$1,451,174
Profits / Employee
$568,587
Market Cap
23.49M
Employees Chart
Related Stocks
Company Name | Employees |
---|---|
Aspira Women's Health | 64 |
Cara Therapeutics | 55 |
Kala Pharmaceuticals | 43 |
Vincerx Pharma | 42 |
GlycoMimetics | 35 |
American Shared Hospital Services | 31 |
iBio, Inc. | 26 |
NeurAxis | 19 |
MEIP News
- 2 months ago - Glancy Prongay & Murray LLP Announces Investigation of MEI Pharma, Inc. (MEIP) - Business Wire
- 2 months ago - MEI Pharma Reports Third Quarter Fiscal Year 2024 Results and Operational Highlights - Business Wire
- 3 months ago - MEI Pharma Board of Directors Aligns on Strategy to Advance Voruciclib and ME-344 - Business Wire
- 3 months ago - MEI Pharma Reports Initial Data from Clinical Study Evaluating ME-344 in Combination with Bevacizumab (Avastin®) in Relapsed Metastatic Colorectal Cancer Patients - Business Wire
- 3 months ago - MEI Pharma to Present at the Stifel 2024 Virtual Targeted Oncology Forum - Business Wire
- 4 months ago - MEI Pharma Reports Update from Clinical Study Evaluating Oral CDK9 Inhibitor Voruciclib in Combination with Venetoclax in Patients with Relapsed and Refractory Acute Myeloid Leukemia - Business Wire
- 5 months ago - MEI Pharma Reports Second Quarter Fiscal Year 2024 Results and Operational Highlights - Business Wire
- 6 months ago - MEI Pharma to Present Design of Ongoing Clinical Study Evaluating ME-344 at ASCO GI Cancers Symposium 2024 - Business Wire